Related references
Note: Only part of the references are listed.Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Katerina Chatzidionysiou et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
V-Region Gene Analysis of Locally Defined Synovial B and Plasma Cells Reveals Selected B Cell Expansion and Accumulation of Plasma Cell Clones in Rheumatoid Arthritis
Tobias Scheel et al.
ARTHRITIS AND RHEUMATISM (2011)
B Cell Activation Biomarkers as Predictive Factors for the Response to Rituximab in Rheumatoid Arthritis
Jeremie Sellam et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Association of the Response to Tumor Necrosis Factor Antagonists With Plasma Type I Interferon Activity and Interferon-β/α Ratios in Rheumatoid Arthritis Patients
Clio P. Mavragani et al.
ARTHRITIS AND RHEUMATISM (2010)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
B cells in the pathogenesis and treatment of rheumatoid arthritis
Bethany Marston et al.
CURRENT OPINION IN RHEUMATOLOGY (2010)
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
K. Visser et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Anti-Citrullinated Peptide Antibody Assays and Their Role in the Diagnosis of Rheumatoid Arthritis
Rohit Aggarwal et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
New therapies for treatment of rheumatoid arthritis
Josef S. Smolen et al.
LANCET (2007)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus
R Eisenberg et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Specific autoantibodies precede the symptoms of rheumatoid arthritis - A study of serial measurements in blood donors
MMJ Nielen et al.
ARTHRITIS AND RHEUMATISM (2004)
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis
S Rantapää-Dahlqvist et al.
ARTHRITIS AND RHEUMATISM (2003)
Evolving concepts of rheumatoid arthritis
GS Firestein
NATURE (2003)
Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years - Results from a large observational inception study
MAS Bukhari et al.
ARTHRITIS AND RHEUMATISM (2003)
Share Paper
